Modality
Degrader
MOA
PD-L1i
Target
BCMA
Pathway
DDR
PBC
Development Pipeline
Preclinical
May 2017
→ Aug 2027
PreclinicalCurrent
NCT05483624
278 pts·PBC
2025-06→2027-08·Completed
NCT06137887
1,018 pts·PBC
2017-05→2026-06·Completed
1,296 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-233mo awayInterim· PBC
2027-08-131.4y awayInterim· PBC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2026-06-23 · 3mo away
PBC
Interim
2027-08-13 · 1.4y away
PBC
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05483624 | Preclinical | PBC | Completed | 278 | Mayo |
| NCT06137887 | Preclinical | PBC | Completed | 1018 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |